AstraZeneca has raised its revenue guidance for the full year after strong sales of its Evusheld Covid-19 antibody treatment and drugs to treat cancer and rare diseases.
The Anglo-Swedish drugmaker now expects total revenue to increase by a low 20s percentage, up from its previous forecast for growth in the high teens. It stuck to its previous guidance for core earnings per share, expecting it to rise by a mid-to-high 20s percentage.
Pascal Soriot, AstraZeneca’s chief executive, said the expected revenue rise would allow the company to boost investment in research and development.
您已閱讀23%（585字），剩餘77%（1928字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。